CAR-T肿瘤免疫治疗[精品课件].pptx,Chimeric antigen receptor (CAR) T-cellImmunotherapy嵌合抗原受体T细胞免疫疗法Presenter:xxxDate: 1. Introduction of CAR-T therapy2. Clinical applications of CAR-T therapy3. Resistance to CAR-T therapy4. Toxicities of CAR-
周末愉快呀! 周六的早晨又“早早”的醒了,真实头大。 感觉不会再睡着了,躺着也只是天马行空的瞎想,索性就起床了,干点实实在在的事,那就先把小文章发了吧。 上一期分享下CAR-T cell结构等,本次分享CAR-T 细…
LOS ANGELES, April 23 (Xinhua) -- An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, according to a new study of the University of Southern Californ...
1.https://www.thedp.com/article/2024/03/penn-emily-whitehead-car-t-cell-therapy-carl-june 2.https://www.onclive.com/view/fda-clears-investigational-new-drug-application-for-tcr-nk-cell-therapy-in-multiple-myeloma ...
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens th
3、Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up[J]. New England Journal of Medicine, 2024, 390(8): 687-700. 4、Tieu V, Sotillo E, Bjelajac J R, et al. A versatile CRISPR-Cas13d platform for multiplexed ...
[9]Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised ph...
近日,宾夕法尼亚大学研究团队就在Cancer Cell期刊报告了这方面的最新研究进展:研究者们提出可使用已获批治疗部分血液系统癌症的EZH1/2抑制剂,在表观遗传层面对癌细胞进行重编程,以增强癌细胞的免疫原性,使用EZH1/2抑制剂在包括实体瘤在内的多种癌症中进行实验,都可与CAR-T或TCR-T疗法实现协同增效[1]。
2025年3月3日,海军医科大学曹雪涛院士的研究团队在期刊《Signal Transduction and Targeted Therapy》上发表了题为“Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation”的研究论文。
近日,宾夕法尼亚大学研究团队就在Cancer Cell期刊报告了这方面的最新研究进展:研究者们提出可使用已获批治疗部分血液系统癌症的EZH1/2抑制剂,在表观遗传层面对癌细胞进行重编程,以增强癌细胞的免疫原性,使用EZH1/2抑制剂在包括实体瘤在内的多种癌症中进行实验,都可与CAR-T或TCR-T疗法实现协同增效[1]。